Roberts, Penumbra EVP, sells $540k in PEN stock

Published 27/11/2025, 01:46
Roberts, Penumbra EVP, sells $540k in PEN stock

Johanna Roberts, Executive Vice President, General Counsel & Secretary at Penumbra Inc (NASDAQ:PEN), sold 1,800 shares of common stock on November 25, 2025, for approximately $540,108. The price per share for the sale was $300.06, with individual transactions ranging from $300.00 to $300.54.

Following the transaction, Roberts directly owns 64,736 shares of Penumbra Inc , a portion of which are subject to vesting. These remaining shares represent a significant stake in the medical device company, which currently maintains a market capitalization of $11.58 billion and carries an elevated P/E ratio of 71.8.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The filing was signed by Emma J. Purdy, as attorney-in-fact for Johanna Roberts, on November 26, 2025. InvestingPro data shows Penumbra maintains a "GREAT" overall financial health score of 3.43, with analysts setting a consensus price target that suggests modest upside potential. For deeper insights and comprehensive analysis, check out the Pro Research Report available for Penumbra, one of 1,400+ US equities covered in-depth.

In other recent news, Penumbra reported impressive third-quarter 2025 financial results, with revenue reaching $354.7 million, marking a 17.8% increase year-over-year and surpassing expectations of $340.91 million. The company’s earnings per share also exceeded consensus estimates, leading management to raise its 2025 revenue guidance. Needham reiterated its Buy rating on Penumbra with a price target of $326, citing strong performance in the thrombectomy segment, which grew by 15% at constant currency. Truist Securities also maintained a Buy rating, increasing its price target to $312 due to robust venous thromboembolism growth of 34%, which balanced slower U.S. stroke trends. Evercore ISI raised its price target slightly to $286, highlighting approximately 17% organic revenue growth to $355 million, with the Embolization segment growing 20.8% organically. These developments indicate strong performance across various segments, contributing to Penumbra’s positive outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.